文献速递慢性肾脏病血液净化与透析

胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭和死亡中的比较有效性

Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.
PubMed 文献 · Am J Kidney Dis · 2025-04-29

本研究为回顾性队列研究,基于台湾全民健康保险研究数据库2016至2021年79,047例2型糖尿病且估算肾小球滤过率<60mL/min/1.73m2的患者,经倾向评分匹配纳入14,182例(GLP-1RA与SGLT2抑制剂各7,091例)。中位随访2.5年,GLP-1RA起始者需肾脏替代治疗风险高于SGLT2抑制剂起始者(HR 1.39;95%CI 1.19-1.63),全因死亡无差异。

要点

  • 在2型糖尿病合并CKD患者中,SGLT2抑制剂起始者进展至需肾脏替代治疗的风险低于GLP-1RA起始者(HR 1.39;95%CI 1.19-1.63)。
  • 两治疗组全因死亡风险无显著差异。
  • 分层分析提示eGFR<45mL/min/1.73m2或尿白蛋白-肌酐比值>300mg/g者两药差异可能更大,但交互检验无统计学显著意义。

核心结论

  • 接受SGLT2抑制剂的患者进展至需肾脏替代治疗的比例低于接受GLP-1RA者,全因死亡无差异。
  • 作者认为这些发现可为慢性肾脏病合并2型糖尿病时选择上述治疗提供参考。

研究设计与样本

  • 回顾性队列研究,使用台湾全民健康保险研究数据库2016至2021年数据。
  • 研究对象为79,047例2型糖尿病且估算肾小球滤过率<60mL/min/1.73m2的患者。
  • 暴露为接受GLP-1RA或SGLT2抑制剂治疗。
  • 采用倾向评分匹配平衡基线特征,匹配后纳入14,182例(GLP-1RA起始7,091例,SGLT2抑制剂起始7,091例)。
  • 采用Cox比例风险模型以意向性治疗方式估计HR和95%CI。

主要发现

  • 中位随访2.5年,GLP-1RA起始者需肾脏替代治疗风险高于SGLT2抑制剂起始者(HR 1.39;95%CI 1.19-1.63)。
  • 两治疗组全因死亡无差异。
  • 交互检验无统计学显著发现,但分层分析提示eGFR<45mL/min/1.73m2或尿白蛋白-肌酐比值>300mg/g者两药差异可能更大。

临床怎么用

  • 原文结论指出,SGLT2抑制剂起始者进展至需肾脏替代治疗的比例低于GLP-1RA起始者,这些发现可为慢性肾脏病合并2型糖尿病时选择上述治疗提供参考。

局限性

  • 非随机治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular, kidney, and survival outcomes in patients with type 2 diabetes; however, the comparative effectiveness of these drugs in a real-world setting remains unclear. STUDY DESIGN: Retrospective cohort study. SETTING & PARTICIPANTS: 79,047 patients with type 2 diabetes and an estimated glomerular filtration rate<60mL/min/1.73m2 in the Taiwan National Health Insurance Research Database between 2016 and 2021. EXPOSURE: Treatment with GLP-1RAs or SGLT2 inhibitors. OUTCOME: Initiation of kidney replacement therapy (KRT) and all-cause mortality. ANALYTIC APPROACH: Propensity score matching was performed to balance baseline characteristics between the groups. Cox proportional hazards models were used to estimate HRs and 95% CIs for each outcome using an intention-to-treat approach. RESULTS: 14,182 (7,091 initiating GLP-1RAs and 7,091 initiating SGLT2 inhibitors) individuals among the original cohort of 79,047 were included in the propensity score-matched analysis. With a median follow-up duration of 2.5 years, people initiating GLP-1RAs had a higher risk of requiring KRT than those initiating SGLT2 inhibitors (HR, 1.39; 95% CI, 1.19-1.63). Although tests of interaction did not have statistically significant findings, stratified analyses suggested possibly greater differences between the 2 drugs among patients with an estimated glomerular filtration rate<45mL/min/1.73m2 or a urine albumin-creatinine ratio>300mg/g. Overall mortality did not differ between treatment groups. LIMITATIONS: Nonrandomized treatment selection. CONCLUSIONS: Patients receiving SGLT2 inhibitors exhibited lower rates of progression to KRT than those receiving GLP-1RAs. These findings may inform the choice of these therapies in the setting of chronic kidney disease and type 2 diabetes. PLAIN-LANGUAGE SUMMARY: Chronic kidney disease is a major complication of type 2 diabetes that often leads to kidney failure and increased mortality. This study aimed to compare the effectiveness of 2 drug classes, glucagon-like peptide-1 receptor agonists and sodium/glucose cotransporter 2 inhibitors, in preventing kidney failure and death in patients with type 2 diabetes and chronic kidney disease. Using a nationwide health database in Taiwan, we applied rigorous statistical methods to balance differences between treatment groups and analyze outcomes. Our findings demonstrated that sodium/glucose cotransporter 2 inhibitors might be more effective than glucagon-like peptide-1 receptor agonists in reducing the risk of kidney failure, and possibly even more so in patients with advanced kidney disease. These results may inform the choice of these agents in the setting of chronic kidney disease and diabetes.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Lee YC, Wu LC, Wu VC, et al. Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD. Am J Kidney Dis. 2025. PMID: 40311668. doi:10.1053/j.ajkd.2025.03.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。